Predicting recurrence and progression in non-muscle-invasive bladder cancer using European organization of research and treatment of cancer risk tables. by Ather, M Hammad & Zaidi, Masooma
Urological Oncology
189Urology Journal    Vol 6    No 3    Summer 2009
Predicting Recurrence and Progression in Non-Muscle-
Invasive Bladder Cancer Using European Organization 
of Research and Treatment of Cancer Risk Tables
M Hammad Ather, Masooma Zaidi
Introduction: We determined the recurrence and progression at 1 year in 
patients with non-muscle-invasive urothelial carcinoma who underwent 
transurethral resection of bladder tumor (TURBT) and compared those with 
the calculated risk according to the European Organization of Research and 
Treatment of Cancer (EORTC).
Materials and Methods: Follow-up data of 92 patients with non-muscle-
invasive bladder cancer who underwent TURBT were reviewed, and their 
1st year recurrence and progression were recorded. The risk of recurrence 
and progression were calculated for 1 year according to the EORTC scoring 
system, using tumors’ stage, grade, size, and multiplicity, and the presence 
of carcinoma in situ and previous recurrence episodes. The outcomes were 
compared with the EORTC’s predictive scores. 
Results: The patients were 75 men and 17 women with an age range of 
31 to 91 years. Sixteen patients (17.4%) had a recurrent disease, 41 (44.6%) 
had a tumor larger than 3 cm in diameter, 35 (38.0%) had multiple lesions, 2 
(2.2%) had carcinoma in situ, 73 (79.3%) had stage T1 lesions, and 8 (8.7%) 
had a high-grade disease. Recurrence was found in 34 patients (37.0%). The 
recurrence rates were 20.0%, 28.2%, 40.5%, and 83.3% in groups with the 
predicted EORTC risks of 15%, 24%, 38%, and 61%, respectively. There 
were 2 patients (2.2%) with progression of the diseases. 
Conclusion: A significant concordance was noted between the EORTC’s 
predicted risk and the actuarial recurrence rate of stage Ta T1 bladder cancer 
at 1 year. Progression was less than that predicted, probably due to our small 
sample size.
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INTRODUCTION 
Bladder carcinoma is the most 
common malignancy of the 
urinary tract.(1) Data from tumor 
registry data analysis of the Armed 
Forces Institute of Pathology, in 
Rawalpindi, Pakistan, showed that 
bladder cancer was the 5th most 
common cancer in men during a 
period between 1992 and 2001.(2) In 
a minimal cancer incidence data for 
Karachi, the largest city of Pakistan, 
for the years 1998 and 1999 indicate 
that tobacco-associated cancers in 
Karachi were responsible for 38.3% 
of the tumors diagnosed amongst 
the men.(3) Approximately 75% to 
85% of patients with bladder cancer 
present with the disease confined 
to the mucosa (stage Ta and 
carcinoma in situ) or submucosa 
(stage T1) with various grades of 
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differentiation.(4) Non-muscle-invasive urothelial 
cell carcinoma of the bladder (UCC) accounts 
for about 80% of all the newly diagnosed cancers.
(1) Transurethral resection of the bladder tumor 
(TURBT) is the gold standard for diagnosis and 
treatment. 
Reported recurrence after TURBT is about 30% 
to 70%.(1) The classic way to categorize patients 
with stage Ta and stage T1 tumors is to divide 
them into risk groups based on prognostic factors 
derived from multivariate analyses. Using such 
a technique, it was proposed to divide patients 
into low-risk, intermediate-risk, and high-risk 
groups.(5) When using these risk groups, however, 
no difference is usually made between the 
risk of recurrence and progression. Although 
prognostic factors may indicate a high risk of 
recurrence, the risk of progression may still be 
low and other tumors may have a high risk of 
both recurrence and progression. In order to 
separately predict the short-term and long-term 
risks of both recurrence and progression in 
individual patients, the European Organization 
for Research and Treatment of Cancer (EORTC) 
developed a scoring system and risk tables.(6) The 
scores can be calculated for each patient according 
to the EORTC recurrence and progression 
predictor table and percentage risk calculated. 
We undertook this study to validate the scoring 
system on our patients with non-muscle-invasive 
UCC. Our aim was to compare the predicted 
(EORTC model) versus actual recurrence 
rate, without taking into consideration the 
maintenance therapy.
MATERIALS AND METHODS 
Patients
This retrospective study was conducted on the 
records at a university hospital between March 
1998 and December 2007, and 178 patients 
with non-muscle-invasive bladder cancer were 
evaluated. They were treated with TURBT and 
diagnosed with stage Ta or stage T1 transitional 
cell carcinoma (TCC) of the bladder based on the 
2002 American Joint Committee on Cancer TNM 
staging system.(7) The grades were determined 
using the 1973 World Health Organization 
system. Patients with a history of muscle-invasive 
bladder cancer treated with a bladder-sparing 
protocol, non-TCC histology, primary carcinoma 
in situ, or a follow-up duration of less than 12 
months were excluded. After exclusions, 92 
patients were enrolled in this study.
Follow-up
Follow-up cystoscopies were done every 3 months 
for the first 2 years in all of the patients, followed 
by a protocol dictated by the risk stratification. 
After 2 years, the follow-up cystoscopies were 
done yearly for 5 years in low-risk patients. In 
high-risk patients, cystoscopies were done every 4 
months during the 3rd year, and every 6 months 
during the 4th and 5th years. Prior to each follow-
up cystoscopy, 2 free voided urine cytology tests 
were performed in order to determine the need 
for random biopsy. 
We collected the clinical and pathological data, 
including sex, age, tumor size (< 3 cm or ≥ 3 
cm), multiplicity (single or multiple), T category 
(Ta or T1), tumor grade, presence of concomitant 
carcinoma in situ or squamous differentiation, and 
intra vesical therapy (single instillation following 
TURBT and maintenance). Follow-up data were 
also obtained, including pathologically proven 
recurrence and time to the first recurrence, which 
was defined as the time period between the date 
of initial diagnosis and the date of recurrence. All 
pathological specimens were routinely assessed in 
the pathology department. Pathologists were not 
blinded to the results of initial pathology report 
or patients’ clinical findings. Patients who were 
still alive or who had died before a recurrence 
were considered as censored at the date of the last 
available follow-up cystoscopy. 
European Organization for Research and 
Treatment of Cancer Scoring
Scores of progression and recurrence risks at 1 
year were calculated for each patient according 
to the EORTC (available from: http://www.
eortc.be/tools/bladdercalculator/).(8) We assessed 
the impact of various clinical and pathological 
features on the outcome of the 1st year. 
Intravesical single instillation of chemotherapy 
(mitomycin C, 40 mg) was given to all patients 
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following initial transurethral resection. 
Maintenance intravesical treatment (either with 
mitomycin C or bacillus Calmette-Guerin) 
was given to the patients with intermediate or 
high risk of progression. In accordance with 
the EORTC model, the impact of either single 
instillation of chemotherapeutic agents following 
TURBT, maintenance intravesical chemotherapy, 
and immunotherapy were not specifically 
assessed. The provided software implements 
the EORTC Scoring System and Risk Tables 
for Stage Ta T1 Bladder Cancer based on the 
data published by Sylvester and colleagues.(6) 
They allow the user to estimate the probability 
of recurrence and progression in patients with 
stages Ta and T1 bladder cancer based on 6 
different factors: number of tumors , tumor size, 
prior recurrence rate, T category, concomitant 
carcinoma in situ, and grade. The endpoint was 
comparison of predicted versus actual recurrence, 
irrespective of the intravesical maintenance 
therapy.
RESULTS 
The median age of the patients was 56 years 
(range, 31 to 91 years), and their median 
follow-up duration was 38 months (range, 12 
to 101 months). They were 75 men (81.5%) 
and 17 women (18.5%). Seventy-one patients 
presented with hematuria (77.2%), 15 with lower 
urinary tract symptoms (16.3%), and 6 with a 
combination of these symptoms (6.5%). Tumor 
characteristics, including primary or recurrent, 
size, number, and pathological characteristics 
are summarized in Table 1. After 1 year, there 
were 34 patients (37.0%) with recurrence of the 
tumor. The recurrence rates after 1 year are listed 
and compared with the predicted EORTC risks 
in Table 2. Progression of the cancer was seen in 
2 patients (2.2%) during the first postoperative 
year. The predicted risks of progression by the 
EORTC in comparison with the progression 
cases are summarized in Table 3. 
DISCUSSION
The clinical management of non-muscle-invasive 
UCC is challenging, as it has a marked tendency 
to recur and to progress. These recurrences are 
most frequent in the first 3 years, but sometimes 
are seen even after long periods of dormancy.(9) 
Regular urological follow-up assessments should 
be continued until at least 15 years of tumor-
free status, especially in patients treated with 
intravesical chemotherapy or in those initially 
having multiple tumors. Prediction of progression 
is made by various tumor characteristics such as 
tumor size, number of tumors, prior recurrence, 
and grade and stage of the disease. These factors 
are incorporated in the EORTC’s developed a 
risk scoring system.(6) Scores were calculated for 
each patient according to the EORTC recurrence 
Characteristics Value (%)
Bladder tumor
Primary 76 (82.6)
Recurrent 16 (17.4)
Tumor size, cm
< 3 51 (55.4)
≥ 3 41 (44.6)
Number of tumors
1 57 (62.0)
2 to 7 28 (30.4)
≥ 8 7 (7.6)
Concomitant carcinoma in situ 2 (2.2)
Tumor stage
Ta 19 (20.6)
T1 73 (79.3)
Tumor grade
1 46 (50.0)
2 38 (41.3)
3 8 (8.7)
Table1. Bladder Tumor Characteristics
EORTC’s Recurrence 
Prediction (Score) Patients
Recurrence After 1 
Year (%)
15% risk (0)  5 1 (20.0)
24% risk (1 to 4) 39 11 (28.2)
38% risk (5 to 9) 42 17 (40.5)
61% risk (10 to 17) 6 5 (83.3)
Table 2. Predicted Versus Actual 1-Year Recurrence Rate*
*Prediction scores were calculated according to the European 
Organization for research and Treatment of Cancer (EORTC).
EORTC’s Progression 
Prediction (Score)
Patients Progression After 1 
Year (%)
0.2% risk (0)  5 0
1% risk (1 to 6) 33 1 (3.0)
5% risk (7 to 13) 51 1 (1.9)
17% risk (14 to 23) 3 0
Table 3. Predicted Versus Actual 1-Year Progression Rate*
*Prediction scores were calculated according to the European 
Organization for research and Treatment of Cancer (EORTC).
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and progression predictor table and percentage 
risk. However, sometimes patients with non-
muscle-invasive UCC are often observed without 
progression in the long-term follow-up period, 
although many of them experience recurrence of 
the disease. It is difficult to accurately predict the 
disease outcome of each patient with conventional 
prognostic criteria. In such situation, Fujikawa and 
colleagues(10) proposed that the use of the artificial 
neural network has a potential to improve the 
prediction. They noted that long-term progression-
free survival of patients with noninvasive TCC 
of the urinary bladder can be precisely predicted 
using the artificial neural network, which would 
be one of the criteria for making decision about 
immediate or future total cystectomy. 
The use of molecular markers and gene expression 
profiling provides a promising approach for 
improving the predictive accuracy of current 
prognostic indexes for predicting progression. In 
order to establish prognostic factors of recurrence 
and progression in stage T1 TCC, paying special 
attention to prognostic value of p53 and ki67 
is suggested by some authors. A group from 
Spain(11) noted that solid microscopic pattern 
and p53 expression are the variables which best 
predict progression. A positive relationship 
was observed between p53 and progression: 
the greater the expression of p53, the greater 
the progression. Tumor multifocality and ki67 
expression of greater than 27% are the main 
prognostic factors for recurrence.(11) Galectin-3 is 
a glycoprotein involved in various physiological 
cellular processes. Altered expression or loss of 
function of galectin-3 is suggested to be involved 
in the pathogenesis and further progression 
of various human cancer entities. Kramer and 
colleagues(12) studied the role of galectin-3 in 
the development and/or progression of non-
muscle-invasive (pTa, pT1) TCC of the bladder. 
They noted that loss of galectin-3 appeared to 
be involved in the carcinogenesis of TCC and to 
serve as a valuable biological variable to identify 
a subgroup of patients with stage Ta bladder 
cancer at a high risk of the development of 
recurrent disease. Baak and colleagues(13) studied 
the predictive value for recurrence and stage 
progression of DNA ploidy and S-phase fraction 
by flow cytometry and highly automated ultrafast 
image cytometry in biopsies of stages Ta and T1 
UCCs of the bladder. They observed that DNA 
image cytometric features predicted recurrence 
and stage progression more accurately than classic 
prognostic factors, independent of treatment 
modality. The clinical significance of various 
molecular markers in predicting prognosis is still 
being debated. Current recommendations of the 
European Association of Urology guidelines(14) are 
to use EORTC risk calculator incorporating.
CONCLUSION
The current work showed that the recurrence 
rates were found to be similar as compared to the 
EORTC model. Progression rates were found 
to be less than that predicted by the scoring 
system, most likely because of the limitations in 
this study, including the small sample size. We 
propose validation of EORTC table in a larger 
cohort for its global applicability.
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